Page 3 - William Windham News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Bexion Pharmaceuticals, Inc to Participate in the 3rd Annual Needham Private Biotech Company Virtual 1x1 Forum

/PRNewswire/ Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a new generation of biologic therapy to treat solid tumor.

William windhamScott shivelyJoyce laviscountBexion pharmaceuticalsBexion pharmaceuticals incPrnewswire bexion pharmaceuticals incNeedham private biotech company virtualSolebury strategic communicationsAnnual needham private biotech company virtualChief financial officer

Bexion Pharmaceuticals, Inc Appoints Dr Catherine Pearce, DHSc, MBA, to Board of Directors

Bexion Pharmaceuticals, Inc Appoints Dr Catherine Pearce, DHSc, MBA, to Board of Directors
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Xavier universityUnited statesJoyce laviscountScott shivelyWilliam windhamCatherine pearceBexion pharmaceuticalsCincinnati children hospital medical centerPrnewswire bexion pharmaceuticals incSolebury strategic communicationsNova southeastern universityDoctorate of health sciences dhscCompany board of directorsTeva pharmaceuticalsBexion pharmaceuticals incBoard of trustees xavier university

Bexion Pharmaceuticals, Inc Appoints Dr Catherine Pearce, DHSc, MBA, to Board of Directors

/PRNewswire/ Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a new generation of biologic therapy to treat solid tumor.

United statesXavier universityWilliam windhamScott shivelyCatherine pearceJoyce laviscountPrnewswire bexion pharmaceuticals incCincinnati children hospital medical centerCompany board of directorsBoard of trustees xavier universityTeva pharmaceuticalsNova southeastern universityBexion pharmaceuticals incDoctorate of health sciences dhscSolebury strategic communicationsBexion pharmaceuticals

Galera Schedules Type A Meeting with FDA to Discuss Next Steps for Avasopasem

MALVERN, Pa., Sept. 18, 2023 Galera Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that.

United statesTimothy bibaMel sorensenChristopher degnanWilliam windhamExchange commissionCompany new drug applicationSolebury strategic communicationsDrug administrationGalera therapeutics incComplete response letterNew drug applicationFast trackBreakthrough therapyOrphan drug designationPrivate securities litigation reform act

Galera Reports Second Quarter 2023 Financial Results and Recent Corporate Updates

Company received Complete Response Letter from FDA for avasopasem and intends to request Type A meeting with FDA to discuss potential next steps Cash runway extended into Q2 2024 in connection with. -Today at 07:02 am- MarketScreener

United statesWilliam windhamChristopher degnanMel sorensenTimothy bibaGalera therapeutics incAmerican society of clinical oncologySolebury strategic communicationsDrug administrationExchange commissionComplete response letterInduced severe oral mucositisNew drug applicationNeck cancerAmerican societyClinical oncology